Ultimately, a therapy is effective only if it treats the clinical issues that matter to patients. NTAP works with patient organizations to enable global clinical studies (e.g., natural history studies, patient reported outcome measure initiatives), thereby identifying patient priorities and ensuring that therapeutic development programs are focused on addressing these key needs.
NTAP fosters relationships across research initiatives where collaborative efforts generate reagents and resources that will accelerate the development of potential therapies against plexiform neurofibromas (pNFs).
Our partners include:
